EVAX
Evaxion Biotech AS
NASDAQ: EVAX · HEALTHCARE · BIOTECHNOLOGY
$4.41
+3.52% today
Updated 2026-04-30
Market cap
$33.61M
P/E ratio
—
P/S ratio
4.47x
EPS (TTM)
$-1.00
Dividend yield
—
52W range
$1 – $12
Volume
0.0M
Evaxion Biotech AS (EVAX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $73000.00 | $3.34M | $7.55M |
| Revenue growth (YoY) | — | — | — | — | — | — | +4480.8% | +125.8% |
| Cost of revenue | $73928.00 | $80984.00 | $105719.00 | $343452.00 | $571319.00 | $112.00 | — | — |
| Gross profit | $-73928.00 | $-80984.00 | $-105719.00 | $-343452.00 | $-571319.00 | $73000.00 | $3.34M | $7.53M |
| Gross margin | — | — | — | — | — | 100.0% | 100.0% | 99.7% |
| R&D | $3.73M | $8.65M | $11.70M | $19.58M | $17.06M | $11.92M | $10.46M | $9.69M |
| SG&A | $1.88M | $2.63M | $5.67M | $6.18M | $8.06M | $10.08M | $7.32M | $6.49M |
| Operating income | $-5.63M | $-11.36M | $-16.57M | $-25.83M | $-25.26M | $-22.20M | $-14.73M | $-9.26M |
| Operating margin | — | — | — | — | — | -30406.8% | -440.6% | -122.7% |
| EBITDA | $-6.18M | $-11.90M | $-16.46M | $-24.21M | $-22.57M | $-21.40M | $-9.79M | $-8.65M |
| EBITDA margin | — | — | — | — | — | -29319.2% | -292.6% | -114.5% |
| EBIT | $-6.25M | $-11.98M | $-16.57M | $-24.55M | $-23.14M | $-22.02M | $-10.39M | $-9.26M |
| Interest expense | $698000.00 | $1.22M | $223000.00 | $915000.00 | $1.51M | $897000.00 | $962000.00 | $878681.00 |
| Income tax | $-735000.00 | $-824837.00 | $-1.56M | $-178000.00 | $-772000.00 | $-790000.00 | $-788000.00 | — |
| Effective tax rate | 11.7% | 6.9% | 9.4% | 0.7% | 3.2% | 3.4% | 6.9% | 0.0% |
| Net income | $-5.54M | $-11.19M | $-15.02M | $-24.53M | $-23.17M | $-22.13M | $-10.57M | $-7.73M |
| Net income growth (YoY) | — | -102.2% | -34.2% | -63.4% | +5.6% | +4.5% | +52.2% | +26.8% |
| Profit margin | — | — | — | — | — | -30308.2% | -316.0% | -102.4% |